To date we have discovered more than 20 promising candidates targeting 7 therapeutic areas. In our journey to find new treatments we established invaluable collaborations with patient groups and organisations, pharmaceutical companies, and academia.

Fraxa & Fraxa-DVI

Purposeful partners with FRAXA and FRAXA-DVI to identify drug repurposing candidates against Fragile X Syndrome. An exciting collaboration that has now led to Purposeful’s first clinical trial.

FRAXA Research Foundation is a nonprofit, tax-exempt organization based in Newburyport, Mass US, committed to finding a cure for Fragile X. FRAXA has funded more than $30 million in biomedical research, yielding discoveries that are changing the lives of families coping with Fragile X. FRAXA is one of the most efficient and effective charities in the world, with management and general expenses under 4 percent. Three Nobel Laureates sit on our volunteer Scientific Advisory Board.

BIOEMTECH

Purposeful partners with BIOEMTECH to identify drug repurposing candidates against Glioblastoma. A series of in-vivo experiments were successfully fulfilled and we are currently planning for next steps.

BIOEMTECH is a pioneer in molecular imaging technology, a rapidly evolving field for clinical and mainly pre-clinical research. BIOEMTECH aims to fulfill the existing needs in imaging equipment and imaging services for small, medium, but also large groups that are active in the field of biotechnology and medical research.

Leo Pharma Ltd

Purposeful collaborated with Leo Pharma Ltd via its Open Innovation to discover and validate drugs to treat Inflammatory and Dermatology indications.

LEO Pharma A/S, a global leader in medical dermatology, and Model Medicines, an AI Drug Discovery company, today announced the launch of an Open Innovation Partnership to discover and validate drugs to treat inflammatory and dermatology indications.